Revive Therapeutics Expands into Phase III Clinical Trials

August 26, 2020

Revive Therapeutics Expands into Phase III Clinical Trials

Revive Therapeutics will expand their candidate, Bucillamine, in patients with mild-moderate COVID-19 in phase III trials taking place in the Asia-Pacific Countries (“APAC”) and Canada. Revive expects to open the Phase 3 clinical trial for patient enrollment and dosing in September 2020. Yourway has a depot in Mississauga, Ontario in Canada, as well as in Beijing, China, Tokyo, Japan, Singapore, and Adelaide, Australia.

Back to Index

Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

Precision in Pharma Supply Chain & Logistics Summit

November 17-18, 2025
Revere Hotel Boston Common

Schedule a Meeting

SCOPE Supply Chain & Logistics Leadership Summit

February 2-5, 2026
Orlando, Florida

Schedule a Meeting

Media

Articles

Mitigating Risk in Drug Development: The Strategic Role of Phase I Research Units

Open chat

Hello! How can I help you?